Home LiteratureArticle Details
PMID: 15998890 Published · ppublish English Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

JAMA ·Vol. 294 ·No. 1 ·2005-07-06 ·Pages 47-55

Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE

Abstract

Basic research and observational evidence as well as results from trials of colon polyp recurrence suggest a role for aspirin in the chemoprevention of cancer. To examine the effect of aspirin on the risk of cancer among healthy women. In the Women's Health Study, a randomized 2 x 2 factorial trial of aspirin and vitamin E conducted between September 1992 and March 2004, 39 876 US women aged at least 45 years and initially without previous history of cancer, cardiovascular disease, or other major chronic illness were randomly assigned to receive either aspirin or aspirin placebo and followed up for an average of 10.1 years. A dose of 100 mg of aspirin (n=19 934) or aspirin placebo (n=19 942) administered every other day. Confirmed newly diagnosed invasive cancer at any site, except for nonmelanoma skin cancer. Incidence of breast, colorectal, and lung cancer were secondary end points. No effect of aspirin was observed on total cancer (n = 2865; relative risk [RR], 1.01; 95% confidence interval [CI], 0.94-1.08; P = .87), breast cancer (n = 1230; RR, 0.98; 95% CI, 0.87-1.09; P = .68), colorectal cancer (n = 269; RR, 0.97; 95% CI, 0.77-1.24; P = .83), or cancer of any other site, with the exception of lung cancer for which there was a trend toward reduction in risk (n = 205; RR, 0.78; 95% CI, 0.59-1.03; P = .08). There was also no reduction in cancer mortality either overall (n = 583; RR, 0.95; 95% CI, 0.81-1.11; P = .51) or by site, except for lung cancer mortality (n = 140; RR, 0.70; 95% CI, 0.50-0.99; P = .04). No evidence of differential effects of aspirin by follow-up time or interaction with vitamin E was found. Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin (100 mg) for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers. A protective effect on lung cancer or a benefit of higher doses of aspirin cannot be ruled out.

MeSH Terms
Aspirin/administration & dosage,therapeutic use Cyclooxygenase Inhibitors/administration & dosage,therapeutic use Double-Blind Method Drug Administration Schedule Female Humans Incidence Middle Aged Neoplasm Invasiveness Neoplasms/epidemiology,mortality,prevention & control Risk Factors
Chemicals
Cyclooxygenase Inhibitors Aspirin
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Cook Nancy R
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. ncook@rics.bwh.harvard.edu
Lee I-Min
Gaziano J Michael
Gordon David
Ridker Paul M
Manson JoAnn E
Hennekens Charles H
Buring Julie E
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
1538-3598
Published
2005-07-06
Pages
47-55
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Grants
NCI NIH HHS · CA-47988 · United States
NHLBI NIH HHS · HL-43851 · United States
Corrections
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com